Comparison of tumor response assessment methods in patients with metastatic colorectal cancer after locoregional therapy

Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver

(2015) Julius Chapiro et al.   EUROPEAN RADIOLOGY

Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis

(2015) Jung Han Kim et al.   Journal of Cancer

Comparison of RECIST 1.0 and RECIST 1.1 on Computed Tomography in Patients with Metastatic Colorectal Cancer

(2014) H.J. Jang et al.   ONCOLOGY

Radiological assessment of response to neoadjuvant transcatheter hepatic therapy with irinotecan-eluting beads (DEBIRI®) for colorectal liver metastases does not predict tumour destruction or long-term outcome

(2013) R.P. Jones et al.   EJSO

Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization

(2013) Eun Suk Jung et al.   JOURNAL OF HEPATOLOGY

Assessment of Chemotherapy Response in Colorectal Liver Metastases in Patients Undergoing Hepatic Resection and the Correlation to Pathologic Residual Viable Tumor

(2013) Michael E. Egger et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)

(2012) H. J. Prajapati et al.   ANNALS OF ONCOLOGY

Why RECIST Works and Why It Should Stay--Reply to Counterpoint

(2012) M. R. Sharma et al.   CANCER RESEARCH

RECIST: No Longer the Sharpest Tool in the Oncology Clinical Trials Toolbox--Point

(2012) M. R. Sharma et al.   CANCER RESEARCH

Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation

(2012) Beom Kyung Kim et al.   EUROPEAN JOURNAL OF CANCER

Radiographic Response to Locoregional Therapy in Hepatocellular Carcinoma Predicts Patient Survival Times

(2011) Khairuddin Memon et al.   GASTROENTEROLOGY

EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization

(2011) Roopinder Gillmore et al.   JOURNAL OF HEPATOLOGY

Which Response Criteria Best Help Predict Survival of Patients with Hepatocellular Carcinoma Following Chemoembolization? A Validation Study of Old and New Models

(2011) Ju Hyun Shim et al.   RADIOLOGY

Hepatic Intra-Arterial Injection of Drug-Eluting Bead, Irinotecan (DEBIRI) in Unresectable Colorectal Liver Metastases Refractory to Systemic Chemotherapy: Results of Multi-Institutional Study

(2010) Robert C. G. Martin et al.   ANNALS OF SURGICAL ONCOLOGY

Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma

(2009) Alejandro Forner et al.   CANCER

Is Selective Internal Radioembolization Safe and Effective for Patients with Inoperable Hepatocellular Carcinoma and Venous Thrombosis?

(2009) Charles E. Woodall et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS